The Effect of tinzaparin on Biomarkers in FIGO Stage III-IV Ovarian Cancer Patients Undergoing Neoadjuvant Chemotherapy – A randomized pilot study

Prior treatment

• Treatment with heparins, low molecular weight heparins or non-vitamin K antagonist oral anticoagulants within the last year.
• Abdominal surgery or other major surgery within the last year

Other illness

• Known or suspected allergies against any product included in the study
• Thromboembolic disease within the last year
• Severe coagulation disorder

Lab values

• Concomitant treatment with heparins, low molecular weight heparins, warfarin or non-vitamin K antagonist oral anticoagulants. Platelet inhibitors are allowed.
• Serious hemorrhage or conditions predisposing to serious hemorrhage. Serious hemorrhage is defined as fulfilling any one of these three criteria: a) occurs in a critical area or organ (e.g. intracranial, intraspinal, intraocular, retroperitoneal, intra-articular or pericardial, intra-uterine or intramuscular with compartment syndrome), b) causes a fall in hemoglobin level of 20 g/L (1.24 mmol/L) or more, or c) leads to transfusion of two or more units of whole blood or red blood cells.
• Platelets <100 x10^9/L (analyzed no more than 14 days before start of treatment with investigational product)
• E-GFR <30ml/min (analyzed no more than 14 days before start of treatment with investigational product)

• Epithelial ovarian, fallopian tube or peritoneal cancer, or abdominal cancer where a biopsy indicates an origin from the ovary, fallopian tube or peritoneum.
• Histology diagnosis of either high grade serous carcinoma, endometroid carcinoma or clear cell carcinoma.
• FIGO stage III-IV disease.
• Planned for platinum-based chemotherapy
• WHO Performance Status 0-2
• CA-125-level ≥250 kIE/L at diagnosis
• Weight 50-150 kg
• Age 18 and above